3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Recurrence
3
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Radiation Pneumonitis
2
Prostatic Neoplasms
2
Mesothelioma, Malignant
2
Lung Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Ovarian Diseases
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Esophagogastric Adenocarcinoma
1
Endometrial Neoplasms
1
Interventions
anlotinib
2
Bevacizumab
2
temsirolimus
1
relacorilant
1
pembrolizumab
1
olaparib
1
niraparib
1
nintedanib
1
lenvatinib
1
Trabectedin
1
Paclitaxel
1
Ocoxin
1
NUC-1031
1
Filgrastim
1
Dexamethasone
1
Carboplatin
1
CP protocol
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ovarian Diseases
×
nintedanib
×
Clear all
NCT01610869
2019-05-29
METRO-BIBF
University College, London
Phase 2
Completed
117 enrolled